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 Abstract
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Background: Since the neurotrophic hypothesis of depression was formulated, conflicting results have been reported regarding the
role of growth factor proteins in depressed patients, including whether there are state or trait alterations found in patients
compared to controls and whether they represent predictors of treatment response. Recently it has been hypothesised that
heterogeneity of findings within this literature might be partly explained by participants’ history of treatment-resistant
depression. This study aimed to investigate the role of growth factor proteins in patients with treatment-resistant depression
(TRD) undergoing an inpatient intervention.
Methods: Blood samples were collected from 36 patients with TRD and 36 matched controls. Patients were assessed both at
admission and discharge from a specialist inpatient program. We examined biomarker differences between patients and
non-depressed matched controls, longitudinal changes after inpatient treatment and relationship to clinical outcomes. Additionally,
the influence of potential covariates on biomarker levels were assessed.  
Results: Patients displayed lower serum levels of brain-derived neurotrophic factor (OR = .025; 95% CI = .001, .500) and vascular
endothelial growth factor-C (VEGFC; OR = .083, 95% CI = .008, .839) as well as higher angiopoietin-1 receptor (Tie2; OR = 2.651, 95%
CI = 1.325, 5.303) compared to controls. Patients were stratified into responders (56%) and non-responders (44%). Lower VEGFD
levels at admission predicted subsequent non-response (OR = 4.817, 95% CI = 1.247, 11.674). During treatment, non-responders
showed a decrease in VEGF and VEGFC levels, while responders showed no significant changes.  
Conclusion: TRD patients demonstrate a deficit of peripheral growth factors and our results suggest that markers of the VEGF
family might decline over time in chronically depressed patients in spite of multidisciplinary treatment. The action of angiogenic
proteins may play an important role in the pathophysiology of TRD, and pending comprehensive investigation may provide
important insights for the future of precision psychiatry.
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Abstract 18 
Background: Since the neurotrophic hypothesis of depression was formulated, conflicting results 19 
have been reported regarding the role of growth factor proteins in depressed patients, including 20 
whether there are state or trait alterations found in patients compared to controls and whether they 21 
represent predictors of treatment response. Recently it has been hypothesised that heterogeneity of 22 
findings within this literature might be partly explained by participants’ history of treatment-resistant 23 
depression. This study aimed to investigate the role of growth factor proteins in patients with 24 
treatment-resistant depression (TRD) undergoing an inpatient intervention.  25 
Methods: Blood samples were collected from 36 patients with TRD and 36 matched controls. 26 
Patients were assessed both at admission and discharge from a specialist inpatient program. We 27 
examined serum biomarker differences between patients and non-depressed matched controls, 28 
longitudinal changes after inpatient treatment and relationship to clinical outcomes. Additionally, the 29 
influence of potential covariates on biomarker levels were assessed.   30 
Results: Patients displayed lower serum levels of brain-derived neurotrophic factor (OR = .025; 95% 31 
CI = .001, .500) and vascular endothelial growth factor-C (VEGFC; OR = .083, 95% CI = .008, .839) 32 
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as well as higher angiopoietin-1 receptor (Tie2; OR = 2.651, 95% CI = 1.325, 5.303) compared to 33 
controls. Patients were stratified into responders (56%) and non-responders (44%). Lower VEGFD 34 
levels at admission predicted subsequent non-response (OR = 4.817, 95% CI = 1.247, 11.674). 35 
During treatment, non-responders showed a decrease in VEGF and VEGFC levels, while responders 36 
showed no significant changes.   37 
Conclusion: TRD patients demonstrate a deficit of peripheral growth factors and our results suggest 38 
that markers of the VEGF family might decline over time in chronically depressed patients in spite of 39 
multidisciplinary treatment. The action of angiogenic proteins may play an important role in the 40 
pathophysiology of TRD, and pending comprehensive investigation may provide important insights 41 
for the future of precision psychiatry. 42 
 43 
 44 
1 Introduction 45 
Major Depressive Disorder (MDD) is now considered the leading cause of disability worldwide 46 
(WHO, 2017). Understanding the pathophysiology of this disorder is essential to optimising 47 
treatment, however the underlying neurobiological mechanisms are still not fully understood. The 48 
neurotrophic and neurogenic hypothesis of depression (Duman et al., 1997) postulates that stress-49 
induced alterations in neurotrophic action mediate reduced adult neurogenesis and volume reductions 50 
in the hippocampus which ultimately increase risk for mood disorders (Duman & Monteggia, 2006). 51 
Antidepressant use is hypothesised to reverse this process and increase the proliferation of progenitor 52 
cells by stimulating the production of growth factors, molecules responsible for neurogenesis and 53 
maintenance of neural networks (Banasr et al., 2011; Castren, 2004).  54 
Evidence for a role of growth factors in the pathophysiology of depression has come from clinical 55 
studies mainly investigating brain derived neurotrophic factor (BDNF), a neurotrophin involved in 56 
processes of neuronal maturation, synapse formation and synaptic plasticity (Duman & Monteggia, 57 
2006), and vascular endothelial growth factor (VEGF or VEGFA), an angiogenic factor also 58 
possessing neurotrophic and neuroprotective properties (Nowacka & Obuchowicz, 2012; Fournier & 59 
Duman, 2012).  60 
Research has reported lower BDNF levels in post-mortem brains of depressed patients compared to 61 
non-depressed controls (Pandey et al., 2008; Karege et al., 2005; Dwivedi et al., 2003), although 62 
these appear to be higher in those patients who had taken antidepressants (Chen et al., 2001). Low 63 
levels of BDNF have also been found in the blood of depressed patients, with increases reported 64 
following antidepressant treatment (Molendjik et al., 2014; Sen et al., 2008; Brunoni et al., 2008).  65 
On the contrary, levels of VEGF tend to be elevated in depressed patients (Carvalho et al., 2015; 66 
Tseng et al., 2015), although a number of studies have reported no significant differences compared 67 
with non-depressed controls (see Clark-Raymond & Halaris, 2013 for a review). The effects of 68 
antidepressants on VEGF are also not clear-cut, with some studies reporting no changes (Clark-69 
Raymond et al., 2016; Halmai et al., 2013; Dome et al., 2012, Ventriglia et al., 2009), one reporting a 70 
decrease (Buttenschøn et al., 2015) and one reporting an increase correlated with improvement of 71 
depressive symptomatology (Ibrahim et al., 2011). 72 
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Recently, resistance to treatment has been suggested as a potential confounding factor in this field of 73 
research (Clark-Raymond & Halaris, 2013). Treatment-resistant depression (TRD) is common and 74 
contributes substantially to the burden of depression (Fekadu et al., 2009a). More pronounced 75 
reductions of proteins central to cellular growth and proliferation might be expected in patients with 76 
TRD, which could be a risk factor and/or consequence of an unsuccessfully treated affective illness. 77 
Indeed, limited research has found lower BDNF levels in TRD than both non-depressed controls and 78 
treatment-responsive patients (Hong et al., 2014). Measuring a similar cohort to the present study, 79 
Carvalho et al. identified non-significantly lower VEGF levels in participants with TRD who did not 80 
go on to respond to an inpatient treatment package than responder participants (p = .058; Carvalho et 81 
al., 2013).  82 
Research to date has not identified sufficiently consistent effects to progress the pathway towards 83 
precision medicine, perhaps in part due to studying heterogeneous depressed groups and limited 84 
trophic biomarker panels. We aimed to address these drawbacks by examining a severe TRD 85 
population (alongside non-depressed, matched controls) and monitoring them during a naturalistic 86 
course of inpatient treatment in addition to a long-term follow-up. Alongside the well-researched 87 
BDNF and VEGF, we also considered six growth factors that play a role in neurogenesis and 88 
maintenance of neural connections but have never been investigated in TRD; due to the scant 89 
evidence in our possession surrounding their role in depression, these comparisons were exploratory 90 
in nature. We therefore test three main two-tailed hypotheses: First, that patients and controls would 91 
differ in levels of growth factors; second, that growth factor levels would change between pre- and 92 
post-treatment assessments; and third, that protein levels would differ between subsequent responders 93 
and non-responders to inpatient treatment.   94 
 95 
2 Material and Methods 96 
This study was approved by the Camberwell & St. Giles NHS Research Ethics Committee (TRD 97 
patients; reference 322/03) and King’s College London Research Ethics Committee (non-depressed 98 
controls; reference PNM/12/13-152). In accordance with the recommendations of the Declaration of 99 
Helsinki, all participants provided written informed consent prior to participation.  100 
2.1 Participants  101 
TRD patients: A cohort of 36 TRD patients were naturalistically recruited and treated within a 102 
specialist inpatient unit for treatment-resistant mood disorders (National Affective Disorders Unit, 103 
South London and Maudsley NHS Foundation Trust, UK). Assessments took place as close as 104 
possible after admission, and before discharge; mean treatment duration 6 months. Patients met 105 
inclusion criteria if they had a primary diagnosis of an affective disorder (unipolar or bipolar) and 106 
were currently depressed, defined as a score ≥ 8 using the Hamilton Depression Rating Scale 107 
(HDRS-17; Hamilton, 1960). The diagnosis was defined following DSM-IV and ICD-10 criteria, 108 
assessed using the Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) and 109 
confirmed by two psychiatrists and a screening of patients’ records. Upon admission, all patients 110 
were treatment-resistant, defined by a score >7.5 using the Maudsley Staging Method (MSM; Fekadu 111 
et al., 2009b), and taking medications. Patients underwent a multidisciplinary intervention, including 112 
pharmacological, psychological and occupational treatment, as well as electroconvulsive therapy 113 
(ECT) in some cases, however not all participants underwent all types of treatment. All patients 114 
completed non-biological measures at both time points, and blood collection at admission; 7 patients 115 
were unavailable for venepuncture measurement at the discharge time point. 116 
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Control participants: 36 non-depressed controls were selected from the South East London 117 
Community Health study (SELCoH) based on closeness of matching to the TRD sample in age, 118 
gender and BMI (see Hatch et al., 2011 for more information regarding the SELCoH study). Control 119 
participants did not meet criteria for current psychiatric disorders measured using the Clinical 120 
Interview Schedule-Revised (Lewis et al., 1992) and did not have significant depressive symptoms as 121 
indicated by a score <10 on the Patient Health Questionnaire (Kroenke et al., 2002). 122 
 123 
2.2 Measures  124 
Biomarkers: Levels of eight different biomarkers were measured: angiopoietin-1 receptor  (Tie2), 125 
brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), vascular 126 
endothelial growth factor-C (VEGFC), vascular endothelial growth factor-D (VEGFD), placental 127 
growth factor (PlGF), basic fibroblast growth factor (bFGF), and soluble fms-like tyrosine kinase-1 128 
(sFlt1; also termed soluble VEGF receptor-1). Blood for serum samples (1x5ml tube) was collected 129 
in the morning between 9-11am. Following complete clotting, the tubes were centrifuged and serum 130 
extracted, transferred into cryovials and frozen (between -40° and -80°C). Serum concentrations of 131 
biomarkers were assayed in duplicate with ultra-high sensitivity Meso Scale Discovery (MSD) V-132 
plex kits (Meso Scale Diagnostics, Maryland, USA), shown to be a reliable measurement tool 133 
(Dabitao et al., 2011). Unless otherwise stated, protein levels are reported in pg/ml. 134 
Non-biological assessments: These were conducted in the TRD group only. Depression severity was 135 
measured using a clinician-administered rating scale (HDRS-17; Hamilton, 1960), with treatment 136 
response defined as more than 50% reduction in scores between admission and discharge time points. 137 
Severity of treatment resistance was assessed at admission using the Maudsley Staging Method 138 
(MSM; Fekadu et al., 2009b). History of childhood adversity was measured using the Childhood 139 
Trauma Questionnaire (CTQ; Bernstein et al., 1994). Cognitive impairment was assessed at 140 
admission using the Mini-Mental State Examination (MMSE; Folstein et al., 1983). Physical health 141 
was assessed at admission using the Modified Cumulative Illness Rating Scale (MCIRS; Salvi et al., 142 
2008), with the total score calculated excluding the item pertaining to mental health. Demographic 143 
data was obtained at admission. Number of medications were recorded at each time point, and 144 
changes during treatment were noted at discharge.  145 
 146 
2.3 Statistical analyses 147 
Raw biomarker data was standardised using logarithmic transformation (base log10) before 148 
undergoing analyses. All data analyses were carried out using bootstrapping, with 1000 generated 149 
samples.  150 
Primary analyses. Logistic regressions and paired t-tests were used to test the primary null 151 
hypotheses, testing differences between responders and non-responders. Conditional logistic 152 
regressions compared the differences in biomarker levels between individually matched TRD patients 153 
and controls at each time point, accounting for gender, age and BMI. Other covariates were 154 
individuated using correlational analyses (see below; secondary analyses) and added to the relevant 155 
regression model if both correlations and unadjusted analyses were significant. Repeated measures 156 
ANOVAs were performed to identify changes in biomarker levels after treatment, using time as the 157 
within-subject variable.  158 
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Due to the number of comparisons, a False Discovery Rate (FDR) control for multiple testing was 159 
applied to primary analyses to reduce the probability of type I error. Thus, uncorrected p values < 160 
0.05 are reported as tentatively significant findings and q values < 0.1 as significant (Benjamini & 161 
Hochberg, 1995).   162 
Secondary analyses. Paired sample t-tests were performed to examine longitudinal changes in the 163 
responder and non-responder groups individually. Pearson’s correlations tested for possible 164 
association between different biomarkers, as well as between biomarkers and potential covariates in 165 
the TRD group, namely depression severity at admission and discharge, childhood trauma, cognitive 166 
impairment, physical health, severity of treatment-resistance, number of medications, and number of 167 
medication changes during inpatient treatment (i.e. starting or stopping an antidepressant medication, 168 
but not changes in dosage). 169 
 170 
3 RESULTS 171 
3.1 Sample characteristics 172 
There was a preponderance of female participants (n = 42; male = 30). Mean age at admission was 173 
54.54 (SD = 13.85). Mean BMI was 28.19 (SD = 5.16). Descriptive statistics for demographic and 174 
biomarker data can be found in Table 1. 20 patients (55.6%) were classified as responders, and 16 175 
patients as non-responders (44.4%). The two subgroups did not differ in other clinical or 176 
sociodemographic factors. Mean values for all measures, including scores from questionnaires, can 177 
be found in supplementary material (supplementary Table 1). 178 
3.2 Biomarker characteristics  179 
As BDNF levels obtained for one participant in the control group did not reach the lowest limit of 180 
detection (LLOD, 30pg/mL; Meso Scale Diagnostics, Maryland, USA), this datum was initially 181 
replaced by half of the LLOD (Hornung & Reed, 1990), but the dataset became highly skewed, thus 182 
this datum was excluded from the dataset. No other biomarker data was outside of detectable limits. 183 
Several variables had slightly skewed or kurtotic distributions; where this affected statistical test 184 
assumptions, the relevant variable was standardised using z scores prior to regression analyses.   185 
3.3 Differences between patients and controls 186 
Conditional logistic regressions demonstrated three biomarkers as significantly different between the 187 
TRD and control groups at both time points. Tie2 was significantly higher in TRD patients 188 
(admission: Χ²(1) = 11.67, p = .006, q = .048; discharge: Χ²(1) = 11.82, p = .010, q = .070). VEGFC 189 
was significantly lower in the TRD group (admission: Χ²(1) = 3.33, p = .045, q = .270; discharge: Χ² 190 
(1) = 7.85, p = .007, q=.056). Lower BDNF was also found in TRD participants (admission: Χ²(1) = 191 
11.92, p = .012, q=.084) but was not significant at discharge (Χ²(1) = 5.56, p = .126). Visual 192 
representations of these differences are depicted in Figure 1. Table 2 details the conditional logistic 193 
regressions used to compare protein levels between these matched groups of  TRD and non-194 
depressed groups. Finally, due to the wide age range we presented scatter plots of BDNF, Tie2 and 195 
VEGFC in correlation with age in patients and controls; these were not significantly related (see 196 
Supplementary Figure 1). 197 
3.4 Biomarkers as predictors of response 198 
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High admission VEGFD predicted response with tentative significance (responder 2.83 ± .17 vs. non-199 
responder 2.69 ± .21 respectively), as shown in Figure 2 (Χ²(1) = 5.38, p = .014, q = .112). A trend 200 
for higher BDNF levels in responders at admission was also found, however it did not reach 201 
significance (p = .067, q = .462).  202 
3.5 Changes following inpatient treatment 203 
Analyses revealed no significant overall differences between biomarker levels at admission and 204 
discharge (pre- and post-treatment protein levels are outlined in Table 1). However, after stratifying 205 
based on response, paired samples t-tests showed that non-responders experienced a decrease in 206 
VEGF and VEGFC during treatment (VEGF: t(11) = 2.87 p = .015, q = .120; VEGFC: t(11) = 2.71, p 207 
= .020, q = .140), while responders’ levels did not change (VEGF: p = .491; VEGFC: p = .957); see 208 
Figure 3.    209 
3.6 Secondary analyses 210 
Two independent samples t-tests compared biomarker levels between patients diagnosed with 211 
unipolar and bipolar depression, both at inpatient admission and discharge. bFGF levels at admission 212 
were higher in unipolar (M = .69, SD = .58) compared to bipolar patients (M = .22, SD = .65); t(34) = 213 
2.19, p = .038. No significant differences were identified at discharge.  214 
Most biomarkers were inter-correlated, with the exception of BDNF which was not correlated with 215 
any other proteins.  216 
Importantly, levels of biomarkers were not associated with depression severity at either time point. 217 
Significant correlations were found between biomarkers and other covariates: Tie-2 levels at 218 
admission positively correlated with BMI (r = .46, p = .024), while admission VEGFC levels were 219 
negatively correlated with both BMI (r = -.45, p = .027) and poorer physical health score (r = -.47, p 220 
= .022). PlGF levels at admission positively correlated with both number of medications (r = .50, p = 221 
.013) and number of changes in medications that occurred subsequently during treatment (r = .44, p = 222 
.029). Similarly, bFGF levels at admission positively correlated with number of medications taken (r 223 
= .50, p = .013) and levels at discharge negatively correlated with number of changes in medication 224 
that had taken place since the baseline research assessment (r = -.55, p = .014). Non-biological 225 
variables did not differ between responders and non-responders (see Supplementary Table 1). 226 
 227 
4 Discussion 228 
The findings from this study may have notable implications for more personalised, predictive 229 
approaches to treatment selection for people with depression who have not responded to multiple 230 
treatments. Results from the main analyses showed that Tie2 levels were higher in TRD patients than 231 
controls, while VEGFC and BDNF were lower in the TRD participants. The BDNF finding replicates 232 
two previous clinical studies on TRD (Bilgen et al., 2014; Hong et al., 2014), which appear to 233 
indicate an association between resistance to pharmacological treatment and extremely low levels of 234 
BDNF, with implications for the role of neurogenesis and neuroplasticity in therapeutic response. If 235 
BDNF expression mediates the action of antidepressants on neural birth and maintenance, patients 236 
with low availability of this growth factor may necessitate other forms of therapy in order to elicit a 237 
meaningful response. The minimisation of this difference by discharge from this specialist inpatient 238 
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programme support this theory, although we note there were not differences identified between 239 
responders and non-responders.  240 
Interestingly, levels of VEGF were not significantly different between patients and controls. Previous 241 
work has found levels of VEGF in depressed patients to be either higher than or the same as those 242 
found in controls (Carvalho et al., 2015; Tseng et al., 2015; Clark-Raymond & Halaris, 2013), and 243 
TRD has been proposed as a potential confounder responsible for this heterogeneity. It has been 244 
suggested that patients with non-resistant depression display higher VEGF levels, representing a 245 
neuroprotective attempt by specific brain structures in response to stress (Clark-Raymond & Halaris, 246 
2013). On the other hand, patients with TRD fail to present this automated reaction, preventing 247 
response to antidepressants. Our data could support this hypothesis by indicating no difference 248 
between VEGF levels in TRD patients and controls, though responders and non-responders also did 249 
not differ in VEGF levels.  250 
VEGFC levels were lower in TRD patients than controls. VEGFC has not yet, to our knowledge, 251 
been investigated in depression, however it belongs to the same protein family of VEGF, and the two 252 
were highly correlated (p < .001). This could indicate that low availability of growth factors 253 
belonging to the VEGF network may be associated with TRD.  254 
Finally, Tie2 was found to be higher in TRD patients compared to controls. Despite the paucity of 255 
data surrounding Tie2’s function in depression (and absence of data in TRD), this result may be 256 
representative of increased inflammatory signalling (Willam et al., 2000), as would be expected in 257 
these patients (Zunszain et al., 2012; Strawbridge et al., 2015). 258 
After stratifying participants based on treatment response, analyses indicated a decrease of VEGF 259 
and VEGFC over time, only in non-responders. Previous studies have found response not to interact 260 
with VEGF changes during pharmacological treatment for non-TRD depressed samples (Clark-261 
Raymond et al., 2016; Halmai et al., 2013; Ventriglia et al., 2009). Our result could suggest that 262 
while an increase in VEGF is not necessary for the therapeutic effects of antidepressants, the non-263 
responders’ decrease may represent a progressive loss of neurotrophic action. It is notable here that 264 
the treatment period averaged at 6 months, which is of longer duration than the majority of previous 265 
research studies within this literature.  266 
No changes were seen in levels of BDNF following antidepressant treatment, contrasting theories 267 
that an increase in the availability of this biomarker is a key mechanism in antidepressant action 268 
(Masi & Brovedani, 2011). It is likely that these inconsistencies stem in part from heterogeneity of  269 
type of treatment, as well as clinical profile and time length between measurement points, as appears 270 
to pervade biological research in depression (Strawbridge et al., 2017). Specifically, all patients were 271 
taking multiple pharmacotherapy throughout the admission and for the majority of patients this 272 
included mood stabilizer medications, which in this sample were far more frequently taken (27/36 273 
patients) than monoaminergic medications (20/36 patients), although both have been posited to 274 
upregulate BDNF (Masi & Brovedani, 2011). 275 
Non-responders displayed significantly lower levels of VEGFD at admission compared to 276 
responders. This is, to our knowledge, the first study to examine VEGFD levels in patients with 277 
depression, but in addition to its angiogenic and lymphangiogenic functions, this protein also helps to 278 
restore and maintain dendritic complexity in the hippocampus (Mauceri et al., 2011). Thus, lower 279 
levels before antidepressant treatment may have contributed to the reduced clinical benefits for non-280 
responder patients. In similar vein, VEGF has been studied as a potential predictor of antidepressant 281 
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response, twice in TRD samples. In a recent study by Clark-Raymond and colleagues (2016) 282 
involving 38 MDD patients, higher VEGF levels were found in remitters, compared to patients who 283 
did not respond to pharmacological therapy. Likewise, Carvalho and colleagues (2013) found a trend 284 
for lower levels of VEGF in a small sample of non-responder TRD patients, and Minelli and 285 
colleagues (2014) found that lower levels of VEGF predicted lack of response to ECT in a large 286 
cohort of 67 TRD patients. In the latter study, VEGF predicted response to ECT but not for another 287 
subgroup of MDD patients receiving pharmacological treatment. The authors argue that these results 288 
indicate a predictive potential of VEGF specific to TRD. Interestingly, higher levels of VEGF have 289 
been found to downregulate the activity of multi-drug resistance transporter at the blood-barrier 290 
(Hawkins et al., 2010), resulting in increased concentrations of exogenous compounds in the brain, 291 
including antidepressants (O’Brien et al., 2012). Thus, a greater availability of VEGF may result in 292 
larger quantity of antidepressant reaching the brain, while low levels of VEGF in TRD patients 293 
(discussed above) may contribute to a low cerebral concentration of antidepressants, insufficient to 294 
produce a therapeutic response (Minelli et al., 2014). The authors argue that ECT boosts VEGF 295 
availability, thus increasing the effectiveness of antidepressants. However, a challenge to this 296 
hypothesis comes from the observation that amelioration of symptoms following ECT is not 297 
associated with an increase in VEGF (Minelli et al., 2011). Thus, the temporal relationship between 298 
these two events with regards to the blood-barrier hypothesis need to be further investigated, as well 299 
as the role played by VEGFD.  300 
 301 
4.1 Limitations and future directions 302 
Not all potentially significant results survived the FDR control for multiple comparisons. It may be 303 
that the smaller effects of biomarkers predicting response in this study were false positive findings, or 304 
that the small sample size and lack of consistently strong inter-correlations between proteins caused 305 
these comparisons to be non-significant after FDR control. It is our hope that future studies will help 306 
to elucidate this. 307 
The naturalistic approach adopted in this study allowed for an unbiased observation of patients within 308 
a realistic clinical environment. The methodological challenges that this presents should be 309 
considered when interpreting these findings. Particularly, data on the type of medication prescribed 310 
for each patient and which treatments were undertaken during the inpatient program were highly 311 
variable and thus challenging to model. The vast majority of TRD participants were undergoing 312 
concomitant treatment with antipsychotics and/or mood stabilisers in addition to monoaminergic 313 
antidepressants, and such combinations may have unknown and unpredictable effects on growth 314 
factor levels. Moreover, data on participation in ECT would have been essential to explore the 315 
hypothesis that ECT leads to greater percentage of medication entering the brain following a 316 
moderation of the permeability of the blood-barrier by VEGF (Minelli et al., 2014). These issues 317 
require further clarification and should be addressed by future studies on TRD. It is also important to 318 
consider that growth factor levels are known to fluctuate in response to a number of variables, 319 
including food intake (Rosas-Vargas et al., 2011), exercise and sedentary behaviour (Kraus et al., 320 
2004; Cotman & Berchtold, 2002), and even the menstrual cycle (Begliuomini et al., 2007), 321 
representing a common limitation in this type of clinical study. Furthermore, it is important to 322 
consider that the TRD and control samples were obtained from two separate studies; as such, 323 
differences in sampling conditions may have affected the results. Finally, reduced follow-up 324 
biomarker data for patients and the small sample size of our study represent clear limitations. Thus, 325 
future research should focus on replicating these findings in larger samples to confirm the importance 326 
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of the VEGF protein family and Tie2, as factors displaying angiogenic properties have the potential 327 
to play a role in the psychopathology of TRD. Furthermore, in order to shed light on potential 328 
differences between TRD and non-refractory depression, controlled studies comparing these two 329 
clinical groups are desirable, possibly adopting a longitudinal design to monitor changes following 330 
discharge. Finally, it has been suggested that our current lack of information on TRD stems mainly 331 
from the post-hoc design of many studies. To solve this issue, it would be helpful to examine patients 332 
at the time of their initial contact with mental health services, and follow them to identify whether 333 
biomarker levels represent a predictor of risk of TRD (Smith, 2013).  334 
 335 
In conclusion, the present study provides support that compounds such as BDNF and VEGF are 336 
important markers in treatment-resistant depression and provides new information on the dynamics 337 
of growth factors in TRD. Specifically, longitudinal activity of VEGF-family members might 338 
represent candidates for stratifying patients based on likelihood of response. Results have highlighted 339 
the importance of angiogenic proteins, which have the potential to represent unique biomarkers of 340 
TRD and may be involved in mechanisms of response. Although replication studies in larger samples 341 
are needed before definitive conclusions can be drawn, findings from this study characterise novel 342 
trophic biomarkers that hold promise as new targets for mood disorder treatment strategies. 343 
 344 
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Table 1: Participant characteristics  521 
 522 
     Non-depressed controls  (n = 36)          TRD patients  (n = 36)                      p-value 
  Log-mean (SD) Range   Log-mean (SD) Range 
  
 
Age  54.48 (13.78) 28 – 80  54.55 (14.30) 26 – 83     0.970 
BMI  28.11 (4.64) 20.20 – 41.60  28.22 (5.75) 18.00 – 46.00     0.930 
Biomarker levels 
(log-pg/ml) 
Pre-treatment 
Tie2 3.57 (.12) 3.32 – 3.84  3.66 (.07) 3.38 – 3.84       0.006* 
PlGF 1.44 (.15) 1.16 – 1.82  1.43 (.13) 1.04 – 1.71     0.547 
VEGF 2.50 (.30) 1.84 – 3.05  2.53 (.41) 1.55 – 3.31     0.652 
VEGFC 2.55 (.15) 2.30 – 2.91  2.45 (.29) 1.72 – 2.85       0.045* 
VEGFD 2.87 (.19) 2.29 – 3.16  2.77 (.20) 2.21 – 3.46     0.087 
bFGF .70 (.31) -.10 – 1.23  .53 (.63) -1.22 – 1.94     0.084 
sFlt1 1.90 (.13) 1.65 – 2.30  1.89 (.12) 1.51 – 2.17     0.627 
BDNF 4.28 (.17) 3.68 – 4.63  4.04 (.37) 3.02 – 4.42       0.012* 
Biomarker levels 
(log-pg/ml) 
Post-treatment 
Tie2    3.68 (.08) 3.57 – 3.88       0.010* 
PlGF    1.48 (.08) 1.30 – 1.64     0.295 
VEGF    2.44 (.57) 1.57 – 3.37     0.728 
VEGFC    2.28 (.48) 1.07 – 2.80       0.007* 
VEGFD    2.79 (.19) 2.08 – 3.22    0.196 
bFGF    0.66 (.53) -.39 – 1.77    0.572 
sFlt1    1.87 (.13) 1.52 – 2.10    0.354 
BDNF    4.10 (.25) 2.98 – 4.40    0.126 
* Different between patients and controls (p < 0.05) 523 
Other factors did not differ between patient and control groups, as indicated by p-values. For TRD patients as a whole group, no biomarker changes 524 
occurred during treatment.   525 
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Table 2: Conditional logistic regression of biomarker levels (TRD versus control group; N=72)  526 
 527 
Biomarker OR X2 
95% Confidence 
Intervals          p 
Lower Upper 
Pre-treatment     
 Tie2 2.651 11.672 1.325 5.303 0.006* 
 PlGF 0.344 0.383 0.011 10.386 0.547 
 VEGF 1.365 0.216 0.366 5.089 0.652 
 VEGFC 0.159 3.327 0.018 1.362 0.045* 
 VEGFD 0.118 3.738 0.011 1.220 0.087 
 bFGF 0.288 2.949 0.124 1.209 0.084 
 sFlt1 0.377 0.273 0.009 15.098 0.627 
 BDNF 0.025 11.921 0.001 0.500 0.012* 
      
Post-treatment     
 Tie2 3.008 11.823 1.308 6.917 0.010* 
 PlGF 1.326 1.156 0.781 2.251 0.295 
 VEGF 0.818 0.123 0.266 2.519 0.728 
 VEGFC 0.083 7.853 0.008 0.839 0.007* 
 VEGFD 0.128 2.064 0.007 2.475 0.196 
 bFGF 0.681 0.413 0.209 2.220 0.572 
 sFlt1 0.201 0.809 0.006 7.007 0.354 
 BDNF 0.028 5.557 0.001 1.338 0.126 
* Different between patients and controls, at both p < 0.05 and q < 0.1. 528 
OR = odds ratio; x2 = Chi-square.  529 
Other factors did not differ between patient (n = 36) and control groups (n = 36) following FDR control for multiple comparisons. 530 
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